Ischemic cerebrovascular disease caused by genetic mutation and patent foramen ovale
Author:
Eruyar Esra1ORCID, Honca Tevfik2ORCID, Bakır Fatih3ORCID
Affiliation:
1. Department of Neurology, Faculty of Medicine , Lokman Hekim University , Çankaya/Ankara , Türkiye 2. Department of Biochemistry , Lokman Hekim Akay Hospital , Ankara , Türkiye 3. Department of Biochemistry, Faculty of Medicine , Lokman Hekim University , Ankara , Türkiye
Abstract
Abstract
Objectives
The search for genetic mutations is very important in younger patients and other age groups with a history of recurrent cerebrovascular diseases (CVD) and a family history of other causes to be excluded. The aim of this study is to define the characteristics of genetic mutations in the etiology of ischemic stroke.
Methods
Twenty-three patients with acute CVD in the last 1 year and only genetic mutations acknowledged in the etiology were retrospectively analyzed. We determined the frequency of the genetic mutations that are observed in cerebral arterial events (CAE) and cerebral venous thrombosis (CVT).
Results
All patients had at least one genetic mutation and 19 of them had arterial events and 4 had venous thrombosis. MTHFR mutation was the most common mutation and PAI-1 mutation was the second in line for the arterial events. PAI 4G/5G, MTHFR A1298 and FV mutations were most frequently observed in venous events. Patent foramen ovale (PFO) was detected in 14 patients (%74) with CAE.
Conclusions
We concluded that multiple gene mutations may significantly increase the development of CVD. CVD is most commonly associated with MTHFR, PAI-1 or FV gene mutations and is most commonly seen in CAE. MTHFR mutations showed moderate linear correlation in the development of arterial events and FXII and FXIII mutations in venous events. The association of thrombophilia and PFO is high in patients who have undergone CAE, especially responsible for recurrent events. This study will need to be confirmed by prospective studies with larger sample and control group.
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,Molecular Biology,Biochemistry
Reference23 articles.
1. Celiker, G, Can, U, Verdi, H, Yazici, AC, Ozbek, N, Atac, FB. Prevalence of thrombophilic mutations and ACE I/D polymorphism in Turkish ischemic stroke patients. Clin Appl Thromb Hemost 2009;15:415–20. https://doi.org/10.1177/1076029608315163. 2. Akar, N, Akar, E, Akçay, R, Avcu, F, Yalcin, A, Cin, S. Effect of methylenetetrahydrofolate reductase 677 C-T, 1298 A-C, and 1317 T-C on factor V 1691 mutation in Turkish deep vein thrombosis patients. Thromb Res 2000;97:163–7. https://doi.org/10.1016/s0049-3848(99)00157-7. 3. Araji, AA, Sawaya, HR, Sawaya, RA. Gene mutations and stroke in the young adult. J Stroke Cerebrovasc Dis 2014;23:2554–8. https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.05.027. 4. Farjat-Pasos, JI, Nuche, J, Mesnier, J, Panagides, V, Cloutier, S, Houde, C, et al.. Transcatheter patent foramen ovale closure in stroke patients with thrombophilia: current status and future perspectives. J Stroke 2022;24:335–44. https://doi.org/10.5853/jos.2022.01697. 5. Mac Grory, B, Ohman, EM, Feng, W, Xian, Y, Yaghi, S, Kamel, H, et al.. Advances in the management of cardioembolic stroke associated with patent foramen ovale. BMJ 2022;376:e063161. https://doi.org/10.1136/bmj-2020-063161.
|
|